Research Paves the Way for New Age-Related Macular Degeneration Treatments

Age-related macular degeneration (AMD) stands as a leading cause of vision impairment among older adults. A crucial characteristic of early AMD is the presence of drusen, which are clusters of debris composed of lipids and proteins that accumulate between two vital layers at the rear of the eye: the retinal pigment epithelium (RPE) and Bruch's membrane (BrM).

These drusen not only signify the presence of the disease but also contribute to vision deterioration by inflicting damage on the retina situated above them. Recent studies have suggested that lipoproteins--complexes of fats and proteins, such as high-density lipoprotein (HDL)--play a significant role in the formation of these drusen. However, the underlying reasons for the entrapment of these lipoproteins in BrM have remained unclear.

A recent study published in the Proceedings of the National Academy of Sciences, led by Christopher B. Toomey, M.D., Ph.D., an assistant professor of ophthalmology at the Shiley Eye Institute, UC San Diego School of Medicine, reveals that heparan sulfate (HS) present in BrM may be instrumental in the early stages of AMD by capturing lipoproteins and initiating drusen formation. By targeting this adhesive interaction, it may be possible to prevent or even reverse the early manifestations of AMD before irreversible vision loss occurs.

The findings indicate that:

• A significantly higher concentration of HS was found in the macular region of BrM in patients with AMD compared to those without the disease.
• Lipoprotein-like particles, including HDL, tended to cluster in regions abundant in HS, suggesting that HS may physically trap these particles.
• When AMD-affected tissue was treated with heparin--a compound similar to HS--the lipoproteins could be removed, supporting the idea that these particles bind to HS.
• The study showed that lipoproteins had a strong affinity for BrM, contingent on the presence of intact HS. Removing HS or using specialized heparin-like molecules halted this binding, indicating the potential for therapeutic agents to disrupt this interaction and mitigate lipoprotein accumulation in BrM.

Additionally, the research highlights the potential of non-blood-thinning forms of heparin as a treatment avenue. These alternatives could effectively eliminate harmful lipids from the eye without the bleeding risks associated with standard heparin.

As the understanding of AMD's mechanisms deepens, these findings open new avenues for developing therapies aimed at the early stages of this debilitating condition, potentially preserving vision in millions of individuals.